CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:Rationale for targeting CELMoDs in NHLMechanism of action of CELMoDsKey studies and available efficacy and safety data with investigational CELMoDs in NHLKey ongoing clinical trials of CELMoDs in NHLStrategies to boost NHL clinical trial diversity among underserved communitiesPresenters: Julio C. Chavez, MD, MSAssociate MemberDepartment of Malignant HematologyICE-T Clinical Research Medical Director for Hematologic MalignanciesH. Lee Moffitt Cancer Center and Research InstituteAssociate ProfessorUniversity of South FloridaTampa, FloridaAlan Skarbnik, MDDirector, Lymphoma and CLL ProgramDirector, Immune Effector Cell Therapeutics ProgramNovant Health Cancer InstituteCharlotte, North CarolinaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb.Link to full program:https://bit.ly/45YXoZI

There are no comments yet.

Please log in to write the first comment.